Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Karen M. Anderson Sells 5,876 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 5,876 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $17.01, for a total value of $99,950.76. Following the sale, the insider now owns 71,525 shares in the company, valued at approximately $1,216,640.25. The trade was a 7.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Centessa Pharmaceuticals Trading Up 5.1 %

NASDAQ CNTA opened at $17.60 on Wednesday. Centessa Pharmaceuticals plc has a 52 week low of $6.65 and a 52 week high of $18.97. The stock has a market cap of $2.32 billion, a P/E ratio of -11.50 and a beta of 1.52. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The company’s fifty day simple moving average is $16.56 and its 200-day simple moving average is $13.46.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. Equities research analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CNTA. B. Riley started coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price objective on the stock. Guggenheim increased their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. BMO Capital Markets lifted their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Jefferies Financial Group increased their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Finally, Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $11.00 to $26.00 in a report on Thursday, September 19th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $25.83.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in CNTA. First Light Asset Management LLC lifted its position in shares of Centessa Pharmaceuticals by 59.2% in the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock worth $43,168,000 after buying an additional 1,778,515 shares during the last quarter. Farallon Capital Management LLC raised its stake in Centessa Pharmaceuticals by 438.0% during the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock worth $18,024,000 after acquiring an additional 1,625,000 shares during the period. Janus Henderson Group PLC bought a new position in Centessa Pharmaceuticals in the third quarter worth about $20,698,000. Franklin Resources Inc. boosted its stake in Centessa Pharmaceuticals by 99.1% in the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after acquiring an additional 1,145,823 shares during the period. Finally, Driehaus Capital Management LLC grew its holdings in shares of Centessa Pharmaceuticals by 89.5% during the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock valued at $18,891,000 after purchasing an additional 987,997 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.